PDCD1 and cervical cancer: In this regard, Liu et al., in 2022, demonstrated that TIGIT is a novel therapeutic target in cervical malignancy; additionally, it plays a significant role in preclinical models of cervical cancer following inhibition of TIGIT by monoclonal antibodies, both alone and in combination with anti-PD-1/PD-L1 antibodies (121).